Fulcrum Therapeutics, Inc. — Form D

Fulcrum Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-06-11. The offering totals $68.5M, of which $68.5M was reported sold. Industry: Biotechnology.

Offering

Filed: 2020-06-11
Form: D
Accession: 0001680581-20-000001
Industry: Biotechnology
Exemptions: 06b
Total offering: $68.5M
Amount sold: $68.5M
Investors: 13
Date of first sale: 2020-06-09
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-368703

Issuer

Name: Fulcrum Therapeutics, Inc.
CIK: 0001680581
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2015
Address: 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Phone: 617-651-8851

Officers, directors & promoters (13)

Name	Role	Location
James Collins	Director	Cambridge, MA
Katina Dorton	Director	Cambridge, MA
Alan Ezekowitz	Director	WATERTOWN, MA
James Geraghty	Director	Cambridge, MA
Robert Gould	Director	Portland, ME
Kate Haviland	Director	Cambridge, MA
Mark Levin	Director	New York, NY
Diego Cadavid	Executive Officer	Cambridge, MA
Robert Gould	Executive Officer	Portland, ME
Bryan Stuart	Executive Officer	Cambridge, MA
Owen Wallace	Executive Officer	Cambridge, MA
James Tananbaum	Director	South San Francisco, CA
Amit Hasija	Executive Officer	Cambridge, MA

Other filings by this issuer (4)

Filed	Form	Offering	Sold
2018-09-05	D	$80.0M	$80.0M
2017-07-25	D/A	$55.0M	$29.7M
2017-05-10	D	$5.0M	$5.0M
2016-07-25	D	$55.0M	$17.0M

More